William J Sandborn Selected Research

infliximab (Remicade)

06/2007	Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
05/2007	Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis.
04/2007	The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
12/2005	Infliximab for induction and maintenance therapy for ulcerative colitis.
10/2004	An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
09/2004	Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease.
05/2004	Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
01/2004	Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease.
01/2004	The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.
10/2003	Management of Crohn's disease of the ileoanal pouch with infliximab.
04/2003	Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize.
12/2002	Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
05/2002	Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion.

28	Crohn Disease (Crohn's Disease) 06/2008 - 01/2002
18	Ulcerative Colitis 08/2008 - 07/2002
10	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2006 - 01/2002
1	Colorectal Neoplasms (Colorectal Cancer) 02/2008
1	Pouchitis 10/2007
1	Microscopic Colitis 08/2006
1	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 09/2004
1	Demyelinating Diseases (Demyelinating Disease) 01/2004
1	Fistula 08/2003
1	Inflammation 06/2003
1	Adult Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 05/2002
1	Delayed Hypersensitivity (Hypersensitivity, Type IV) 05/2002
1	Lymphoma (Lymphomas) 01/2002

13	infliximab (Remicade)FDA Link 06/2007 - 05/2002
8	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2008 - 12/2003
8	Mesalamine (Mesalazine)FDA LinkGeneric 01/2007 - 01/2002
5	Azathioprine (Imuran)FDA LinkGeneric 10/2005 - 01/2002
5	6-Mercaptopurine (Mercaptopurine)FDA LinkGeneric 10/2005 - 01/2002
4	adalimumab (Humira)FDA Link 06/2007 - 10/2004
3	natalizumab (Tysabri)FDA Link 12/2007 - 11/2005
3	Budesonide (Pulmicort)FDA LinkGeneric 01/2006 - 01/2002
2	CDP870 FDA Link 07/2007 - 07/2007
2	Tacrolimus (Prograf)FDA Link 06/2004 - 08/2003
1	salicylhydroxamic acid (SHAM)IBA 08/2008
1	Nonesterified Fatty Acids (NEFA)IBA 04/2008
1	rifaximin (L 105)FDA Link 10/2007
1	recombinant human tumor necrosis factor-binding protein-1IBA 07/2006
1	celecoxib (Celebrex)FDA Link 02/2006
1	C-Reactive ProteinIBA 08/2005
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 06/2004
1	mycophenolate mofetil (Cellcept)FDA LinkGeneric 06/2004
1	6-thioguanylic acidIBA 07/2003
1	Biological Markers (Surrogate Marker)IBA 07/2003
1	LactoferrinIBA 06/2003
1	AntibodiesIBA 04/2003
1	ProdrugsIBA 12/2002
1	N-acetyltransferase 1IBA 07/2002
1	Sulfasalazine (Azulfidine)FDA LinkGeneric 07/2002
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 04/2002

4	Blood Component Removal (Apheresis) 08/2008 - 12/2005
2	Colectomy 07/2008 - 09/2002
2	Biological Therapy 12/2007 - 05/2002
1	Remission Induction 01/2007
1	Cholecystectomy 08/2006
1	Appendectomy 08/2006
1	Chemoprevention 01/2006